Kissei Pharmaceutical Co., Ltd.

As of March 31, 2026, Kissei Pharmaceutical Co., Ltd. carries a market capitalization of 192.75B, placing it among publicly traded companies globally. Its enterprise value stands at 140.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kissei Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 4, 2026.

As of March 31, 2026, Kissei Pharmaceutical Co., Ltd. has 41.45M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Kissei Pharmaceutical Co., Ltd. maintains a current ratio of 5.30, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Kissei Pharmaceutical Co., Ltd.'s stock has declined approximately 8.18% over the past 52 weeks. The 50-day moving average sits at 3,957.70, while the 200-day moving average is 4,289.00.

As of March 31, 2026, Kissei Pharmaceutical Co., Ltd. holds 54.42B in cash and equivalents against 1.25B in total debt, resulting in a net debt position of -27.81B. Total book value stands at 230.15B, with working capital of 93.28B providing operational flexibility.

Kissei Pharmaceutical Co., Ltd.'s most recent stock split took place on March 26, 1996 with a 10:11 split ratio.